Alzamend Neuro
Quarterly Financials
| Values in thousands | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -27 | -27 | -27 | -12 |
EBITDA | -2,169 | -970 | -2,672 | -1,126 |
EBIT | -2,197 | -998 | -2,700 | -1,138 |
Net Income | -2,198 | -1,000 | -2,702 | -1,139 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -1,736 | -1,171 | -2,362 | -898 |
Cash | 2,713 | 4,449 | 5,620 | 3,948 |
Basic Shares | 3,804 | 3,380 | 2,106 | 711 |
Annual Financials
| Values in thousands | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -50 | -50 | -23 | |
EBITDA | -4,446 | -9,887 | -14,847 | -12,316 |
EBIT | -4,496 | -9,937 | -14,870 | -12,319 |
Net Income | -4,514 | -9,948 | -14,878 | -12,362 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -8,922 | 12,134 | ||
Free Cash Flow | -6,868 | -8,417 | -8,923 | -6,720 |
Cash | 3,948 | 376 | 5,140 | 14,063 |
Basic Shares | 450 | 75 | 72 | 65 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-01-31 | -$0.58 |
2025-10-31 | -$0.30 |
2025-07-31 | -$1.28 |
2025-04-30 | -$9.48 |
